This population decreased significantly after steroid treatment, suggesting that CD19+CD24−CD38hi plasmablasts/plasma cells may be a biomarker of IgG4-RD and potentially could be useful in confirming a diagnosis, monitoring response to therapy, or assessing disease activity. This evidence concerns the gene CD19 and immunoglobulin G4-related sclerosing disease.